Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience
| dc.contributor.author | Ward, Natalie | |
| dc.contributor.author | Pang, J. | |
| dc.contributor.author | Ryan, J. | |
| dc.contributor.author | Watts, G. | |
| dc.date.accessioned | 2018-08-08T04:43:03Z | |
| dc.date.available | 2018-08-08T04:43:03Z | |
| dc.date.created | 2018-08-08T03:50:54Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Ward, N. and Pang, J. and Ryan, J. and Watts, G. 2018. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clinical Cardiology. 41 (1): pp. 159-165. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/69973 | |
| dc.identifier.doi | 10.1002/clc.22862 | |
| dc.description.abstract |
There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C–lowering therapy in statin-intolerant patients, with evidence from our own clinical practices. | |
| dc.title | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience | |
| dc.type | Journal Article | |
| dcterms.source.volume | 41 | |
| dcterms.source.number | 1 | |
| dcterms.source.startPage | 159 | |
| dcterms.source.endPage | 165 | |
| dcterms.source.issn | 0160-9289 | |
| dcterms.source.title | Clinical Cardiology | |
| curtin.department | School of Public Health | |
| curtin.accessStatus | Fulltext not available |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||